Cell line · CVCL_1430
MSTO-211H
Cancer cell line, Homo sapiens. Pleural biphasic mesothelioma. 34 papers.
4 sourcescell-lines-2026-11-14-0.1.0
Download JSON
Cite this record
ConductScience Library. MSTO-211H. Cell lines, record CVCL_1430. Release cell-lines-2026-11-14-0.1.0, 14 Nov 2026. https://conductscience.org/library/cell-lines/CVCL_1430
On this page
Cell line
As Cellosaurus gives it.
- Name
- MSTO-211H
- Accession
- CVCL_1430
- RRID
- RRID:CVCL_1430
- Synonyms
- MSTO-211 H, MSTO211H, MSTO-211, 211H, MeSoTheliOma-211H
- Species
- Homo sapiens (Human)
- Sex
- Male
- Age at sampling
- 62Y
- Category
- Cancer cell line
- Diseases
- Pleural biphasic mesothelioma (NCIt C45665); Pleural mesothelioma (ORDO Orphanet_50251)
- Derived from
- Pleural effusion (in situ)
- Entry created
- 2012-04-04
- Entry updated
- 2025-04-10
Source Cellosaurus
Problems0
Cellosaurus records no problem for this cell line.
None in this release.
Papers34
1 more article gives this line's RRID in its Methods without naming the line nearby, so it is not listed.
| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| Nuclear Factor-κB Signaling in Murine Models of Malignant Pleural Mesothelioma. | Cancers (Basel) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| A convergent uPAR-positive tumor ecosystem creates broad vulnerability to CAR T cell therapy. | Cell | 2026 | Its Methods give the RRID and name the line | PubMed | |
| BAG2, MAD2L1, and MDK are cancer-driver genes and candidate targets for novel therapies in malignant pleural mesothelioma. | Cancer Gene Ther | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Identification of resistance mechanisms to small-molecule inhibition of TEAD-regulated transcription. | EMBO Rep | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Low Exposures to Amphibole or Serpentine Asbestos in Germline Bap1-mutant Mice Induce Mesothelioma Characterized by an Immunosuppressive Tumor Microenvironment. | Cancer Res Commun | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Effects of Combined Therapeutic Targeting of AXL and ATR on Pleural Mesothelioma Cells. | Mol Cancer Ther | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Genetic screens reveal new targetable vulnerabilities in BAP1-deficient mesothelioma. | Cell Rep Med | 2023 | Its Methods give the RRID and name the line | PubMed | |
| Analysis of Primary Cilium Expression and Hedgehog Pathway Activation in Mesothelioma Throws Back Its Complex Biology. | Cancers (Basel) | 2022 | Its Methods give the RRID and name the line | PubMed | |
| Pan-cancer proteomic map of 949 human cell lines. | Cancer Cell | 2022 | Cellosaurus cites it | PubMed | |
| Picropodophyllin inhibits the growth of pemetrexed-resistant malignant pleural mesothelioma via microtubule inhibition and IGF-1R-, caspase-independent pathways. | Transl Lung Cancer Res | 2022 | Its Methods give the RRID and name the line | PubMed |
1 to 10 of 34
See all 34 papersRelatives1
| Relation | Cell line | Accession | Problem |
|---|---|---|---|
| Derived from it | Ubigene MSTO-211H LDHA KO | CVCL_E0ZC |
Source Cell lines
Cell banks5
Data dates
The date of each source this release read.
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this cell line from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_1430
GET https://conductscience.org/api/cell-lines/v1/CVCL_1430/papers?page=2